Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
  • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• 5-HT- receptors one of the subtypes of serotoninergic receptors, play an important physiological role. Also, as the various chapters of the book “Brain 5-HT Receptors: Behaviourai and Neurochemical Pharmacology” show (Editors C.T. Dourish, S. Ahlenins, P.H. Hutson,
• 5-HT 1A agonists may be useful for the treatment of anxiety, depression, sleep disorders, vascular and cardiovascular disorders, and the regulation of food.
• Agonists 5-HT-. are also known as inhibitors of gastric secretion (JS Gidda, JM Schaus EP.455.510 A2, 1991).
• the present invention carried out at the Pierre Fabre Research Center, relates to new chemical compounds endowed with agonist activity at 5-HT 1 ⁇ receptors, their preparation and their therapeutic application.
• A represents an oxygen atom, a sulfur atom, or a methylene radical; m can take the values of 0 or 1;
• B represents a carbonyl function (CO) or a methylene
• n can take the values of O or 1; R represents a cycloalkyy radical, monocyclic or polycyclic, C O -C- Q .
• the invention also relates to the salts of the compounds of general formula _ with pharmaceutically acceptable mineral or organic acids.
• the acid employed can be, by way of nonlimiting example, p-toiuessesulfonique acid, or fumaric acid.
• the present invention relates to both racemic mixtures and the various enantiomers of the compounds of general formula _1_ as well as their mixtures in all proportions.
• the compounds of general formula _1_ where B represents a carbonyl radical can be prepared according to the reaction scheme:
• - X represents a water-repellent group such as methylsulfonyloxy, benzenesulfonyloxy, or jo-toluenesulfonyloxy.
• reaction between a compound of general formula 2 ⁇ and a compound of general formula 3 ⁇ is carried out either in the absence or in the presence of a solvent such as toluene, xylene, dimethylformamide or acetonitrile, preferably at a temperature between 50 ° C and 200 ° C, and optionally in the presence of an organic base such as a tertiary or mineral amine, such as an alkali carbonate or hydro-carbonate.
• a solvent such as toluene, xylene, dimethylformamide or acetonitrile
• a compound of general formula 4_ obtained according to the methods described above, is carried out by means of a simple or complex hydride of boron or aluminum, for example, 1 * double hydride of lithium and d aluminum, a diborane / ether complex, or the diborane / methyl sulfide complex, or any other equivalent means, in an inert solvent such as ethyl ether or tetrahydrofuran.
• the reduction can be carried out at room temperature or accelerated by heating to the reflux temperature of the solvent.
• a compound of general formula 5_ is thus obtained which corresponds to the general formula j_ when B represents a methylene.
• R cyclohexyl
• X p_-toluenesulfonyloxy
• the compounds of the invention have been subjected to pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.
• rat cerebral cortices are used.
• the brain is dissected and the cortex is homogenized in 20 volumes of Tris-HCl buffer (50 mil, pH 7.4 at 25 ° C) maintained at 4 ° C.
• the homogenate is centrifuged at 39,000 xg for 10 minutes, the centrifugation pellet is suspended in the same volume of buffer and centrifuged again. After resuspending under the same conditions, the homogenate is incubated for 10 minutes at 37 ° C and then centrifuged again.
• the final pellet is suspended in 80 volumes of reaction buffer containing: pargyline (10 -5 M), CaCl 2 (4 mM) and ascorbic acid (0.1%) in Tris-HCl (50 mM, pH 7 , 4 at 25 ° C).
• the final concentration of tissue in the incubation medium is 10 mg / tube.
• the reaction tubes contain 0.1 ml of different concentrations of ⁇ 3 H_7 ⁇ -OH-DPAT (between 0.06 and 8 nM), 0.1 ml of reaction buffer or 5-HT (10 M, to determine non-specific binding) and 0.8 ml of tissue.
• Displacement experiments are carried out as described by Sleight and Peroutka (Naunyn-Schneideberg Arch. Pharmacol., 343, 106-116, 1991). All the dilutions of the products to be studied are made in the reaction buffer.
• the reaction tubes contain 0.1 ml of J_H_ / 8-OH-DPAT (0.2 nM), 0.1 ml of product to be tested 6-7 concentrations (successive dilutions to 1/10) and 0.8 ml tissue. If the alleged affinity of the products is in the nanomo- laire, the lowest concentration tested is 10-11 M, if the product has an assumed low affinity, the highest concentration tested is 10 -4 M.
• reaction tubes are incubated at 23 ° C for 30 minutes and then rapidly filtered under vacuum on hatman GF / B filters, the tubes are rinsed with 2 x 5 ml of Tris-HCl buffer (50 mM, pH 7.4 at 25 ° C).
• the radioactivity collected on the filter is analyzed in liquid scintillation by adding 4 ml of scintillating liquid
• the dissociation constant (K D ) and the maximum number of binding sites (Bmax) for the radio frequency are estimated from the saturation experiments using the non-linear regression program EBDA / LIGAND (Biosoft) (Munson and Rodbard, Anal. Biochem., 107, 220-239, 1980).
• the affinity constants (Ki) of the reference products are estimated from the displacement experiments using the non-linear regression program EBDA / LIGAND. This method admits that the value of the Hiil coefficient is not different from unity.
• the data from the displacement experiments are analyzed respectively with the one site and two site models and the calculated F makes it possible to determine whether the two site model is more representative of the data obtained than the one site model.
• the pKi values are given as an average + SEM of 3 to 5 experiments.
• Table 2 gives, by way of example, pKi 5-HT 1A for certain derivatives of the invention, compared with Buspirone which is used in clinical practice.
• Table 2 Affinity for the 5-HT-A receptor
• the central activity of the compounds of the invention has been evaluated by their capacity to cause 5-HT syndrome, which is characterized by alternating flexion and extension of the front legs (reciprocal fore-paw treading: FPT), the re ⁇ traction of the lower lip (lower-lip retraction: LLR) and by a posture where the ventral surface of the animal is in contact with the floor of the cage with the extended hind legs (flat body posture: FBP).
• the compounds of the invention can therefore be useful for the treatment of anxiety, depression, sleep disorders, for the regulation of food intake, for the regulation of gastric secretion, and for the treatment of vascular disorders.
• cardiovascular and cerebrovascular such as hypertension or migraine.
• Pharmaceutical preparations containing these active ingredients can be shaped for administration by oral, rectal or parenteral route, for example in the form of capsules, tablets, granules, capsules, liquid solutions, syrups or oral suspensions, and contain the appropriate excipients.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Pain & Pain Management (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Child & Adolescent Psychology (AREA)
• Heart & Thoracic Surgery (AREA)
• Anesthesiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9443949

Family Applications (1)

Country Status (8)

Families Citing this family (6)

Family Cites Families (4)

• 1993
  • 1993-02-11 FR FR9301525A patent/FR2701479B1/fr not_active Expired - Fee Related
• 1994
  • 1994-02-10 WO PCT/FR1994/000152 patent/WO1994018193A1/fr not_active Application Discontinuation
  • 1994-02-10 JP JP6517735A patent/JPH08506334A/ja active Pending
  • 1994-02-10 CA CA002155849A patent/CA2155849A1/fr not_active Abandoned
  • 1994-02-10 NZ NZ261331A patent/NZ261331A/en unknown
  • 1994-02-10 ZA ZA94910A patent/ZA94910B/xx unknown
  • 1994-02-10 EP EP94906261A patent/EP0683775A1/de not_active Withdrawn
  • 1994-02-10 AU AU60033/94A patent/AU6003394A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events